ESTRO 2022 - Abstract Book

S1226

Abstract book

ESTRO 2022

1 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Radiotherapy Department, Gliwice, Poland; 2 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, III Department of Radiotherapy and Chemotherapy, Gliwice, Poland; 3 Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Biostatistics and Bioinformatics, Gliwice, Poland Purpose or Objective Plantar fasciitis (PF) is a skeletal disorder of the plantar fascia which affects patients quality of life due to the pain and mobility problems. Because it is one of the most common foot complaint it is a significant social problem. Radiotherapy (RT) represents a relevant method. The aim of the study was to evaluate efficacy and safety of RT in the treatment of PF. Materials and Methods From the patients treated at the single-institution we retrospectively included 41 patients (54 cases) who were irradiated to a total dose of 6Gy given in 6 fractions five times weekly. Several aspects concerning: symptoms duration before RT, pain localization (the extent) and adverse effects of RT were assessed. The effectiveness of radiotherapy was assessed using the numerical pain rating scale NRS (NRS- numerical rating scale) and German Cooperative Group on Radiotherapy for Non-malignant Diseases (GCG-BD). Results The follow-up was 2 years. Taking into account the NRS scale, the mean value of pain after RT decreased in relation to the baseline value during the follow-up period. Before RT, the mean NRS score was 8.5 (range 3-10). Immediately after RT and 3 months after RT, mean scores of 4.8 (range 0-10) and 1.1 were recorded, respectively. During the control period 6-24 months, the mean value of pain according to NRS was 1.1 and subsequently 1.5. Before starting the therapy, the average value according to GCG-BD was 35,2 (range 5-59) what was related to severe pain and significant quality of life deterioration. Immediately after RT and 3, 6, 12 and 24 months after RT the mean value according to GCG-BD was higher (symptoms deterioration and improvement of function) at 59.4 (range 5-100), 88.5 (range 17-100), 88.6 (range 17-100), 92.4 (range 25-100) and 89.5 (range 24-100), respectively. After 24 months pain relief was observed in 89% of patients, including 75.5% with complete pain relief and quality of life improvement even higher than that achieved shortly after RT. This confirms the need for longer time follow up and evaluation of the response to treatment without additional unnecessary therapy since long lasting effects can be found. Analysis of the prognostic factors has shown that only localized pain significantly predicts greater pain relief effect of RT (p<0.05). Other analysed factors for example: duration of symptoms, previous non-RT treatment, type of professional activities were not significant. Mild skin dryness was the only early side effect, observed only in 4% of cases. No late toxicity and secondary malignances were observed. _msocom_1 Conclusion Radiotherapy for Plantar Fascitis is an effective treatment providing long lasting pain relief and functional improvement without significant toxicity and secondary malignances. Localized pain seems to be positive predictive factor for the effect of therapy. 1 Copenhagen University Hospital - Herlev-Gentofte, Department of Oncology, Copenhagen, Denmark; 2 Copenhagen University Hospital - Herlev and Gentofte, Department of Oncology, Copenhagen, Denmark; 3 Copenhagen University Hospital - Rigshospitalet, Department of Oncology, Copenhagen, Denmark; 4 Copenhagen University, Department of Clinical Medicine, Copenhagen, Denmark; 5 Copenhagen University Hospital- Herlev and Gentofte, Department of Oncology, Copenhagen, Denmark Purpose or Objective A third of patients with non-small cell lung cancer (NSCLC) develop brain metastases (BM). The prognosis for this patient group is historically poor. National guidelines recommend whole brain irradiation (WBI) in case of > 5 BM. However, for patients with a short life expectancy it is important to consider treatment with supportive care alone. The introduction of immune check point inhibitors (CPI) and targeted therapies have increased life expectancies for the majority of patients with NSCLC, but it is unknown if this is the case after WBI. This benchmarking study examines overall survival after WBRT in a real-world cohort of patients with NSCLC with focus on identifying subgroups of patients who do not benefit from WBRT. Materials and Methods Patients who received WBRT from July 2016 to June 2019, at two oncology departments were included for analysis. Patients ID were retrieved from the radiotherapy treatment planning system. Clinical information was retrieved from electronic patient charts. Overall survival was measured from start of WBRT and estimated using Kaplan-Meier. The following variables were included in a Cox proportional hazards regression model to identify prognostic variables: Age, gender, performance status, histopathological subtype including PD-L1 status. Results 257 patients were included in the study. Median age was 66 years (range 40-94) at time for WBRT. and 41.6% were men. A large majority (83.6%) had adenocarcinoma, whereof 11.3% had EGFR or ALK mutations, 6.2% had squamous cell carcinoma and 3.9% had NSCLC not otherwise specified (NOS). PD-L1 expression was > 50% in 20,6%, 1-50% in 16.7%, <1% in 36.2% and unknown in 26.1% of patients. WHO performance status where PS0 in 15.6%, PS1 in 25.9%, PS2 in 31.9% and PS3 in 6.6%. PO-1446 PD-L1 and histopathological subtype have no impact on survival after whole brain irradiation F. Sundbye 1 , K. Skougaard 2 , M. Pøhl 3 , A. Mann Nielsen 2 , G. Persson 4,5